首页> 外文期刊>Cardiovascular Research >Preventive effects of pravastatin on thrombin-triggered vascular responses via Akt/eNOS and RhoA/Rac1 pathways in vivo.
【24h】

Preventive effects of pravastatin on thrombin-triggered vascular responses via Akt/eNOS and RhoA/Rac1 pathways in vivo.

机译:普伐他汀在体内通过Akt / eNOS和RhoA / Rac1途径对凝血酶触发的血管反应的预防作用。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS: Small GTPases RhoA and Rac1 play crucial roles in endothelial dysfunction and reactive oxygen species (ROS) generation. We reported evidence that in thrombin-stimulated endothelial cells, rapid geranylgeranylation is an essential process for full activation of unprocessed RhoA, which is blocked by statin. In this study, we examined the effects of intravenous administration of pravastatin on thrombin-triggered vascular responses in vivo, as well as on the lipid modification of unprocessed forms of RhoA and Rac1 and their activation induced by thrombin. METHODS AND RESULTS: Thrombin (50 U/kg) was intravenously injected with or without 0.3 mg/kg pravastatin into Wistar and spontaneously hypertensive rats. Coadministration of pravastatin prevented thrombin-induced impaired endothelium-dependent coronary vasodilation and down-regulated Akt/endothelial nitric oxide synthase (eNOS) phosphorylation within 1 h, as well as the down-regulation of eNOS protein expression within 4 h. In addition, thrombin increased Rac1/p47(phox)-dependent NAD(P)H oxidase activities of rat aortas within 1 h, resulting in ROS generation, which was prevented by the coadministration of pravastatin. Furthermore, the coadministration of pravastatin prevented thrombin-induced conversion of unprocessed RhoA and Rac1 into the geranylgeranylated forms as well as GTP-loading and membrane translocation within 1 h. CONCLUSION: Intravenous injection of pravastatin prevents impaired NO-dependent vasodilation and Rac1/NAD(P)H oxidase-mediated-ROS generation by blocking the down-regulation of Akt/eNOS pathways and the full activation of unprocessed RhoA and Rac1 in vivo.
机译:目的:小型GTPases RhoA和Rac1在内皮功能障碍和活性氧(ROS)产生中起关键作用。我们报道的证据表明,在凝血酶刺激的内皮细胞中,快速的香叶基香叶基化是完全激活未处理的RhoA(由他汀类药物阻断)的必要过程。在这项研究中,我们检查了静脉注射普伐他汀对凝血酶触发的体内血管反应的作用,以及对未经加工的RhoA和Rac1形式的脂质修饰以及凝血酶诱导的活化的影响。方法和结果:向Wistar和自发性高血压大鼠静脉注射凝血酶(50 U / kg),加或不加0.3 mg / kg普伐他汀。普伐他汀的共同给药可防止凝血酶诱导的内皮依赖性冠状血管舒张受损和Akt /内皮一氧化氮合酶(eNOS)磷酸化水平下调,并在4 h内下调eNOS蛋白表达。此外,凝血酶可在1小时内增加大鼠主动脉的Rac1 / p47(phox)依赖性NAD(P)H氧化酶活性,从而导致ROS的产生,这可通过普伐他汀的共同给药来预防。此外,普伐他汀的共同给药可防止凝血酶诱导的未加工的RhoA和Rac1转化为香叶基香叶基化形式,以及在1小时内GTP负载和膜移位。结论:静脉注射普伐他汀可通过阻断Akt / eNOS通路的下调以及体内未处理的RhoA和Rac1的完全活化,防止NO依赖性血管舒张受损和Rac1 / NAD(P)H氧化酶介导的ROS生成。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号